Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization

Vaccine

Volumn 28, Issue 48, 2010, Pages 7659-7666

  Ralli Jain, Pooja ^a   Tifrea, Delia ^a   Cheng, Chunmei ^a   Pal, Sukumar ^a   de la Maza, Luis M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chlamydia trachomatis; Mice; Recombinant major outer membrane protein; Respiratory infections; Systemic and mucosal immunization; Vaccine

Indexed keywords

BACTERIAL VACCINE; CHLAMYDIA TRACHOMATIS VACCINE; CHOLERA TOXIN; CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; MONTANIDE; NEISSERIA GONORRHOEAE RECOMBINANT PORIN B; RECOMBINANT MAJOR OUTER MEMBRANE PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHLAMYDIAL PNEUMONIA; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; LUNG; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; WEIGHT CHANGE;

ADMINISTRATION, SUBLINGUAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; BACTERIAL VACCINES; BODY WEIGHT; CD4-POSITIVE T-LYMPHOCYTES; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; FEMALE; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; LUNG; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PORINS; SPLEEN; VACCINES, SYNTHETIC;

EID: 78249250867     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.040     Document Type: Article

References (59)

1. Miller W.C., Ford C.A., Morris M., Handcock M.S., Schmitz J.L., Hobbs M.M., et al. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA 2004, 291(May (18)):2229-2236.
2. Chlamydia screening among sexually active young female enrollees of health plans-United States, 2000-2007. MMWR Morb Mortal Wkly Rep 2009, 58(April (14)):362-365.
3. Darville T. Chlamydia trachomatis genital infection in adolescents and young adults. Adv Exp Med Biol 2006, 582:85-100.
4. Grayston J.T., Wang S.P. The potential for vaccine against infection of the genital tract with Chlamydia trachomatis. Sex Transm Dis 1978, 5(April-June (2)):73-77.
5. Schachter J., Dawson C.R. Human chlamydial infections 1978, Publishing Science Group, Chicago.
6. Grayston J.T. Symposium on trachoma. Biology of the virus. Invest Ophthalmol 1963, 2(October):460-470.
7. Stamm W. Chlamydia trachomatis infections of the adult. Sexually transmitted diseases 2008, 575-593. McGrawHill Book, Co., New York. K.K. Holmes, P.F. Sparling, W.E. Stamm, P. Piot, J.W. Wasserheit, L. Corey, M.S. Cohen, D.H. Watts (Eds.).
8. Westrom L., Joesoef R., Reynolds G., Hagdu A., Thompson S.E. Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis 1992, 19(July-August (4)):185-192.
9. Ness R.B., Soper D.E., Holley R.L., Peipert J., Randall H., Sweet R.L., et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002, 186(May (5)):929-937.
10. Ness R.B., Smith K.J., Chang C.C., Schisterman E.F., Bass D.C. Prediction of pelvic inflammatory disease among young, single, sexually active women. Sex Transm Dis 2006, 33(March (3)):137-142.
11. Brunham R.C., Pourbohloul B., Mak S., White R., Rekart M.L. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. J Infect Dis 2005, 192(November (10)):1836-1844.
12. de la Maza L.M., Peterson E.M. Vaccines for Chlamydia trachomatis infections. Curr Opin Investig Drugs 2002, 3(July (7)):980-986.
13. Somani J., Bhullar V.B., Workowski K.A., Farshy C.E., Black C.M. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis 2000, 181(April (4)):1421-1427.
14. Wang S.P., Grayston J.T., Alexander E.R. Trachoma vaccine studies in monkeys. Am J Ophthalmol 1967, 63(May (Suppl. (5))):1615-1630.
15. Grayston J.T., Wang S. New knowledge of chlamydiae and the diseases they cause. J Infect Dis 1975, 132(July (1)):87-105.
16. Caldwell H.D., Kromhout J., Schachter J. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect Immun 1981, 31(March (3)):1161-1176.
17. Grayston J.T., Wang S.P., Yeh L.J., Kuo C.C. Importance of reinfection in the pathogenesis of trachoma. Rev Infect Dis 1985, 7(November-December (6)):717-725.
18. Morrison R.P., Lyng K., Caldwell H.D. Chlamydial disease pathogenesis. Ocular hypersensitivity elicited by a genus-specific 57-kD protein. J Exp Med 1989, 169(March 3):663-675.
19. Caldwell H.D., Kromhout J., Schachter J. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect Immun 1981, 31(March 3):1161-1176.
20. Baehr W., Zhang Y.X., Joseph T., Su H., Nano F.E., Everett K.D., et al. Mapping antigenic domains expressed by Chlamydia trachomatis major outer membrane protein genes. Proc Natl Acad Sci USA 1998, 85(June 11):4000-40004.
21. Cheng C., Bettahi I., Cruz-Fisher M.I., Pal S., Jain P., Jia Z., et al. Induction of protective immunity by vaccination against Chlamydia trachomatis using the major outer membrane protein adjuvanted with CpG oligodeoxynucleotide coupled to the nontoxic B subunit of cholera toxin. Vaccine 2009, 27(October (44)):6239-6246.
22. Pal S., Peterson E.M., de la Maza L.M. Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect Immun 2005, 73(December (12)):8153-8160.
23. Pal S., Theodor I., Peterson E.M., de la Maza L.M. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect Immun 2001, 69(October (10)):6240-6247.
24. Kari L., Whitmire W.M., Crane D.D., Reveneau N., Carlson J.H., Goheen M.M., et al. Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine. J Immunol 2009, 182(June (12)):8063-8070.
25. Sun G., Pal S., Weiland J., Peterson E.M., de la Maza L.M. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein. Vaccine 2009, 27(August (36)):5020-5025.
26. de la Maza M.A., de la Maza L.M. A new computer model for estimating the impact of vaccination protocols and its application to the study of Chlamydia trachomatis genital infections. Vaccine 1995, 13(January (1)):119-127.
27. Nigg C. An unidentified virus which produces pneumonia and systemic infection in mice. Science 1942, 95(January (2454)):49-50.
28. Pal S., Fielder T.J., Peterson E.M., de la Maza L.M. Protection against infertility in a BALB/c mouse salpingitis model by intranasal immunization with the mouse pneumonitis biovar of Chlamydia trachomatis. Infect Immun 1994, 62(August (8)):3354-3362.
29. Marston F.A. The purification of eukaryotic polypeptides synthesized in Escherichia coli. Biochem J 1986, 240(November (1)):1-12.
30. Blake M.S., Gotschlich E.C. Purification and partial characterization of the opacity-associated proteins of Neisseria gonorrhoeae. J Exp Med 1984, 159(February (2)):452-462.
31. Qi H.L., Tai J.Y., Blake M.S. Expression of large amounts of neisserial porin proteins in Escherichia coli and refolding of the proteins into native trimers. Infect Immun 1994, 62(June (6)):2432-2439.
32. Schagger H., von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100kDa. Anal Biochem 1987, 166(November (2)):368-379.
33. Song J.H., Nguyen H.H., Cuburu N., Horimoto T., Ko S.Y., Park S.H., et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci USA 2008, 105(February (5)):1644-1649.
34. Amorij J.P., Westra T.A., Hinrichs W.L., Huckriede A., Frijlink H.W. Towards an oral influenza vaccine: comparison between intragastric and intracolonic delivery of influenza subunit vaccine in a murine model. Vaccine 2007, 26(December (1)):67-76.
35. McConnell E.L., Basit A.W., Murdan S. Colonic antigen administration induces significantly higher humoral levels of colonic and vaginal IgA, and serum IgG compared to oral administration. Vaccine 2008, 26(January (5)):639-646.
36. Weeratna R.D., McCluskie M.J., Xu Y., Davis H.L. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 2000, 18(March (17)):1755-1762.
37. Peterson E.M., Zhong G.M., Carlson E., de la Maza L.M. Protective role of magnesium in the neutralization by antibodies of Chlamydia trachomatis infectivity. Infect Immun 1988, 56(April (4)):885-891.
38. Srivastava I., Goodsell A., Zhou F., Sun Y., Burke B., Barnett S., et al. Dynamics of acute and memory mucosal and systemic immune responses against HIV-1 envelope following immunizations through single or combinations of mucosal and systemic routes. Vaccine 2008, 26(May (22)):2796-2806.
39. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6(February (2)):148-158.
40. Bryan J.T. Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine 2007, 25(April (16)):3001-3006.
41. Riddiough M.A., Sisk J.E., Bell J.C. Influenza vaccination. JAMA 1983, 249(June (23)):3189-3195.
42. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348(May (18)):1737-1746.
43. Walker M., Szmuness W., Stevens C.E., Rubenstein P. Genetics of anti-HBs responsiveness. I. HLA-DR7 and nonresponsiveness to hepatitis vaccination. Transfusion 1981, 21:601.
44. Lang J., Kamga-Fotso L., Peyrieux J.C., Blondeau C., Lutsch C., Forrat R. Safety and immunogenicity of a new equine tetanus immunoglobulin associated with tetanus-diphtheria vaccine. Am J Trop Med Hyg 2000, 63(November-December (5-6)):298-305.
45. Lin H.H., Liao H.W., Lin S.K., Wang L.Y. HLA and response to booster hepatitis B vaccination in anti-HBs-seronegative adolescents who had received primary infantile vaccination. Vaccine 2008, 26(June (27-28)):3414-3420.
46. Schachter J. Infection and disease epidemiology. Chlamydia: intracellular biology, pathogenesis and immunity 1999, 139-170. ASM, Washington. R. Stephens (Ed.).
47. Mestecky J., Moldoveanu Z., Smith P.D., Hel Z., Alexander R.C. Mucosal immunology of the genital and gastrointestinal tracts and HIV-1 infection. J Reprod Immunol 2009, 83(December (1-2)):196-200.
48. Mestecky J., Russell M.W. Induction of mucosal immune responses in the human genital tract. FEMS Immunol Med Microbiol 2000, 27(April (4)):351-355.
49. Mestecky J., Elson C.O. Peyer's patches as the inductive site for IgA responses. J Immunol 2008, 180(February (3)):1293-1294.
50. Kelly K.A., Chan A.M., Butch A., Darville T. Two different homing pathways involving integrin beta7 and E-selectin significantly influence trafficking of CD4 cells to the genital tract following Chlamydia muridarum infection. Am J Reprod Immunol 2009, (April).
51. Pal S., Peterson E.M., de la Maza L.M. Intranasal immunization induces long-term protection in mice against a Chlamydia trachomatis genital challenge. Infect Immun 1996, 64(December (12)):5341-5348.
52. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004, 350(February (9)):896-903.
53. Cuburu N., Kweon M.N., Hervouet C., Cha H.R., Pang Y.Y., Holmgren J., et al. Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. J Immunol 2009, 183(December (12)):7851-7859.
54. Cuburu N., Kweon M.N., Song J.H., Hervouet C., Luci C., Sun J.B., et al. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 2007, 25(December (51)):8598-8610.
55. Ogra P.L., Karzon D.T. Distribution of poliovirus antibody in serum, nasopharynx and alimentary tract following segmental immunization of lower alimentary tract with poliovaccine. J Immunol 1969, 102(June (6)):1423-1430.
56. Vajdy M., Singh M., Ugozzoli M., Briones M., Soenawan E., Cuadra L., et al. Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations. Immunology 2003, 110(September (1)):86-94.
57. Barnett S.W., Srivastava I.K., Kan E., Zhou F., Goodsell A., Cristillo A.D., et al. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 2008, 22(January (3)):339-348.
58. Vajdy M., Baudner B., Del Giudice G., O'Hagan D. A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza. Clin Immunol 2007, 123(May (2)):166-175.
59. Vajdy M., Singh M., Kazzaz J., Soenawan E., Ugozzoli M., Zhou F., et al. Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. AIDS Res Hum Retroviruses 2004, 20(November (11)):1269-1281.